Sarepta Elevidys EU Rejection

News

Sarepta Shares Fall

Sarepta shares drop after EU regulators reject Elevidys gene therapy

Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Elevidys,

Bloomberg on MSN · 4d

Sarepta Shares Fall After EU Regulator Rejects Gene Therapy

Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment in the US.

The Business Journals · 18h

Sarepta's FDA woes raise questions for future of gene therapy treatments

Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy is a nail in the coffin for gene therapy.

Investing.com South Africa4d

Sarepta stock falls after Elevidys fails to get backing by EU regulators

The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...

BioSpace4d

Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

Fierce Pharma6d

Roche halts Elevidys distribution in some countries, following Sarepta's lead in US

Roche is pausing shipments of Elevidys in some countries, following partner Sarepta Therapeutics’ move in the U.S., as safety ...

Yahoo Finance3mon

Sarepta Therapeutics Provides Update on ELEVIDYS

CAMBRIDGE, Mass., April 04, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS ...

Business Insider3mon

Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS

Sarepta (SRPT) Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular dystrophy. Following the safety update on acute liver ...

Seeking Alpha3mon

Sarepta stock down on EU clinical hold (update) (SRPT:NASDAQ)

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy Elevidys after a patient death. Read more here.

Benzinga.com3mon

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe ... - Benzinga

Sarepta and Roche paused multiple Elevidys trials in the EU at the EMA’s request. HC Wainwright upgraded Sarepta to Neutral but sees Elevidys sales falling by Q2 2025. Up Next: Get 5 Dark ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results